Clinical Rheumatology

, Volume 25, Issue 5, pp 749–752

Rasburicase treatment in severe tophaceous gout: a novel therapeutic option

  • J. D. Moolenburgh
  • M. K. Reinders
  • T. L. Th. A. Jansen
Case Report

DOI: 10.1007/s10067-005-0043-y

Cite this article as:
Moolenburgh, J.D., Reinders, M.K. & Jansen, T.L.T.A. Clin Rheumatol (2006) 25: 749. doi:10.1007/s10067-005-0043-y


We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.


Gout Rasburicase Review Urate oxidase 

Copyright information

© Clinical Rheumatology 2005

Authors and Affiliations

  • J. D. Moolenburgh
    • 1
  • M. K. Reinders
    • 2
  • T. L. Th. A. Jansen
    • 3
  1. 1.Department of RheumatologyMedical Centre AlkmaarAlkmaarThe Netherlands
  2. 2.Department of Clinical Pharmacy and PharmacologyMedical Centre LeeuwardenBR LeeuwardenThe Netherlands
  3. 3.Department of RheumatologyMedical Centre LeeuwardenBR LeeuwardenThe Netherlands

Personalised recommendations